Clarity Pharmaceuticals ASX Update Advances Prostate Cancer Treatment Development

Key Highlights

• Clarity achieves its SECuRE trial recruitment target, advancing its experimental prostate cancer treatment program.
• Earlier clinical findings demonstrate 81% disease control, with further patient outcomes awaiting assessment.
• FY26 revenue climbs 68%, although increased research spending contributes to widening financial losses.

SECuRE Trial Reaches Major Recruitment Milestone

Clarity Pharmaceuticals Limited (ASX: CU6), an Australian clinical-stage biotechnology company specialising in radiopharmaceutical development, announced on 8 October 2026 that it had achieved its recruitment target for the main expansion group of the Phase I/IIa SECuRE trial. The development advances the Company's experimental treatment program for metastatic castration-resistant prostate cancer.

The study's main expansion group includes 16 participants undergoing evaluation of up to six treatment cycles involving 8 GBq of copper-67 SAR-bisPSMA. Recruitment continues for additional participants receiving the investigational therapy alongside enzalutamide, allowing researchers to examine the potential benefits of combining both treatments.

Earlier Clinical Findings Show Encouraging Responses

Previously reported clinical findings indicated promising treatment activity among participants receiving copper-67 SAR-bisPSMA.

Key observations included:

• 74% of evaluable participants achieved prostate-specific antigen reductions of at least 25%.
• 63% recorded PSA declines of at least 50%, while 26% achieved reductions of at least 90%.
• 81% of 16 radiographically evaluable participants demonstrated disease control.

Across the broader development program, seven participants achieved complete responses or undetectable disease.

Despite these encouraging observations, further clinical investigation remains necessary to establish long-term treatment effectiveness.

FY26 Financial Results Highlight Rising Development Expenditure

Earlier, on 27 August 2026, Clarity released its preliminary financial results for the year ended 30 June 2026. Revenue from ordinary activities increased 68% to AU$8.00 million. However, the annual loss attributable to shareholders widened 67% to AU$107.24 million, compared with AU$64.30 million in FY25.

Research and development expenditure increased AU$24.20 million to AU$91.10 million, reflecting expanding clinical programs and commercial preparations. Meanwhile, liquid assets reached AU$178.30 million, comprising AU$57.20 million in cash and AU$121.00 million in term deposits.

Outlook and Future Prospects

Clarity intends to advance its SECuRE program while preparing for a potential Phase III therapeutic trial. Anticipated results from its CLARIFY and AMPLIFY diagnostic studies in early 2027 could provide further direction for regulatory development.

Although its financial resources support continued research, clinical uncertainties, regulatory requirements and substantial development expenditure remain important considerations. Future trial outcomes will be critical in determining the Company's potential commercialisation opportunities.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au